Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 25 of 235 entries
View as:

aHUS Observational Long Term Follow-Up

Phase: N/A Priority: Normal
NCT ID: NCT01522170 Org: User:
Start: 03/31/12 End: 01/31/17 Due: 01/31/18

Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Sebelipase Alfa in Children With Growth Failure Due to Lysosomal Acid Lipase Deficiency

Phase: N/A Priority: Normal
NCT ID: NCT01371825 Org: User:
Start: 05/04/11 End: 01/03/18 Due: 01/03/19

Study in Adult and Pediatric Patients With HSCT-TMA

Phase: N/A Priority: Normal
NCT ID: NCT04970004 Org: User:
Start: 07/12/21 End: 04/01/22 Due: 04/01/23

A Phase 3 Open-Label Study of Eculizumab in Pediatric Participants With Refractory Generalized Myasthenia Gravis (gMG)

Phase: N/A Priority: Normal
NCT ID: NCT03759366 Org: User:
Start: 12/28/18 End: 11/06/23 Due: 11/06/24

Acid Lipase Replacement Investigating Safety and Efficacy (ARISE) in Participants With Lysosomal Acid Lipase Deficiency

Phase: N/A Priority: Normal
NCT ID: NCT01757184 Org: User:
Start: 01/22/13 End: 12/11/18 Due: 12/11/19

A Drug Interaction Study Between Danicopan and Midazolam, Fexofenadine, and Mycophenolate Mofetil in Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT03108274 Org: User:
Start: 04/18/17 End: 06/16/17 Due: 06/16/18

Paroxysmal Nocturnal Hemoglobinuria (PNH) Registry

Phase: N/A Priority: Normal
NCT ID: NCT01374360 Org: User:
Start: 10/29/04 End: 08/06/24 Due: 08/06/25

Drug Interaction Study of ALXN2050 With Fluconazole and Rifampin in Healthy Adult Participants

Phase: N/A Priority: Normal
NCT ID: NCT04933682 Org: User:
Start: 06/23/21 End: 08/04/21 Due: 08/04/22

Study of ALXN2050 in Adult Participants With Generalized Myasthenia Gravis

Phase: N/A Priority: Normal
NCT ID: NCT05218096 Org: User:
Start: 04/27/22 End: 04/03/24 Due: 04/03/25

Study of Danicopan as Add-on Treatment to Ravulizumab or Eculizumab in Pediatric Participants With PNH Who Have Clinically Significant Extravascular Hemolysis

Phase: N/A Priority: Normal
NCT ID: NCT06449001 Org: User:
Start: 09/30/25 End: 07/31/28 Due: 07/31/29

Mitigate Immune-Mediated Loss of Therapeutic Response to Asfotase Alfa (STRENSIQ®) for Hypophosphatasia

Phase: N/A Priority: Normal
NCT ID: NCT06015750 Org: User:
Start: 07/02/25 End: 02/14/29 Due: 02/14/30

Safety and Tolerability, Pharmacokinetic, and Pharmacodynamic Study of ALXN1920 in Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT05751642 Org: User:
Start: 04/19/23 End: 12/04/23 Due: 12/04/24

Study of ALXN2050 in Healthy Adult Participants of Japanese Descent

Phase: N/A Priority: Normal
NCT ID: NCT04952545 Org: User:
Start: 07/09/21 End: 09/07/21 Due: 09/07/22

Phase 1/2a Dose Escalation Study in Participants With CLL, SLL, or NHL

Phase: N/A Priority: Normal
NCT ID: NCT01994382 Org: User:
Start: 08/30/13 End: 12/15/20 Due: 12/15/21

Safety Study of Human Recombinant Tissue Non-Specific Alkaline Phosphatase Fusion Protein Asfotase Alfa in Adults With Hypophosphatasia (HPP)

Phase: N/A Priority: Normal
NCT ID: NCT00739505 Org: User:
Start: 08/31/08 End: 02/28/09 Due: 02/28/10

Study of Danicopan in Participants of Japanese Descent

Phase: N/A Priority: Normal
NCT ID: NCT04451434 Org: User:
Start: 08/17/20 End: 09/28/20 Due: 09/28/21

Safety, Tolerability, and Antiviral Activity of ACH-0141625 or Placebo in Combination With Peginterferon and Ribavirin in Hepatitis C Virus (HCV) Positive Participants

Phase: N/A Priority: Normal
NCT ID: NCT01180790 Org: User:
Start: 09/30/10 End: 04/30/13 Due: 04/30/14

A Study to Evaluate the Safety and Tolerability of CAEL-101 in Patients With AL Amyloidosis

Phase: N/A Priority: Normal
NCT ID: NCT04304144 Org: User:
Start: 03/18/20 End: 11/14/23 Due: 11/14/24

Effect of Pexelizumab on All-Cause Mortality and Myocardial Infarction in Patients Undergoing Coronary Artery Bypass Graft Surgery With Cardio-Pulmonary Bypass

Phase: N/A Priority: Normal
NCT ID: NCT00048308 Org: User:
Start: 01/31/02 End: - Due: -

A Study to Investigate the Pharmacokinetic Profile of ALXN2050 Modified Release Prototype Formulations and Immediate Release Reference Tablet in Healthy Adult Participants

Phase: N/A Priority: Normal
NCT ID: NCT05780645 Org: User:
Start: 03/15/23 End: 02/26/24 Due: 02/26/25

Phase IIa Trial of ALXN1007 for the Treatment of Non-criteria Manifestations of Antiphospholipid Syndrome

Phase: N/A Priority: Normal
NCT ID: NCT02128269 Org: User:
Start: 04/30/14 End: 06/30/16 Due: 06/30/17

Study of Ultomiris® (Ravulizumab) Safety in Pregnancy

Phase: N/A Priority: Normal
NCT ID: NCT06312644 Org: User:
Start: 12/18/24 End: 10/24/34 Due: 10/24/35

Study of Danicopan in Participants With Hepatic Impairment

Phase: N/A Priority: Normal
NCT ID: NCT03555539 Org: User:
Start: 05/01/18 End: 09/21/18 Due: 09/21/19

Open Label Controlled Trial of Eculizumab in Adolescent Patients With Plasma Therapy-Sensitive aHUS

Phase: N/A Priority: Normal
NCT ID: NCT00844428 Org: User:
Start: 07/31/09 End: 12/31/13 Due: 12/31/14

Study of Ravulizumab in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)

Phase: N/A Priority: Normal
NCT ID: NCT04564339 Org: User:
Start: 01/19/21 End: 05/27/26 Due: 05/27/27